PHAR — Pharming Group N.V.
$11.20+4.97%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for PHAR in the TickerWise workspace.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: NL
- Exchange: NASDAQ
- Employees: 404
- Website: https://www.pharming.com
Latest SEC filings for PHAR
Latest PHAR news
- Pharming reports Q3 revenue Read article
- Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026 Read article
- Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes Read article
- Pharming CEO Fabrice Chouraqui steps down Read article
- Pharming announces CEO transition Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.